Patents by Inventor TORSTEN A E FALK

TORSTEN A E FALK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLYCOPEPTIDES AND USES THEREOF
    Publication number: 20190060399
    Abstract: The present invention provides glycopeptides comprising a peptide that is covalently linked to a saccharide. The peptide portion of the glycopeptides of the invention has from about 20 to about 40 amino acid residues and at least 75% sequence identity to SEQ ID NO:1, 2, or 3. The saccharide moiety portion of the glycopeptides of the present invention comprises from 1 to about 8 carbohydrates. The present invention also relates to using the glycopeptides of the invention in treating various neurodegenerative diseases.
    Type: Application
    Filed: November 5, 2018
    Publication date: February 28, 2019
    Inventors: Robin L. Polt, Torsten A E Falk, Michael L. Heien, John Streicher
  • Glycosylated PACAP/VIP analogues with enhanced CNS penetration for treatment of neurodegenerative diseases
    Patent number: 10117907
    Abstract: A glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) which can both agonize PAC1 receptors, causing neuroprotective effects, and antagonize VPAC receptors, causing anti-inflammation in several models of acute neuronal damage and neurodegenerative diseases, including ALS, PD, migraines, and certain forms of dementia, is described. Also described is a method of relieving symptoms of ALS, PD, migraines, and certain forms of dementia, comprising administering to a subject in need thereof an effective amount of a glycosylated PACAP.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: November 6, 2018
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona, a body corporate
    Inventors: Robin Polt, Torsten A E Falk
  • GLYCOSYLATED PACAP/VIP ANALOGUES WITH ENHANCED CNS PENETRATION FOR TREATMENT OF NEURODEGENERATIVE DISEASES
    Publication number: 20160166639
    Abstract: A glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) which can both agonize PAC1 receptors, causing neuroprotective effects, and antagonize VPAC receptors, causing anti-inflammation in several models of acute neuronal damage and neurodegenerative diseases, including ALS, PD, migraines, and certain forms of dementia, is described. Also described is a method of relieving symptoms of ALS, PD, migraines, and certain forms of dementia, comprising administering to a subject in need thereof an effective amount of a glycosylated PACAP.
    Type: Application
    Filed: February 16, 2016
    Publication date: June 16, 2016
    Inventors: ROBIN POLT, TORSTEN A E FALK